Table 1. Characteristics of breast tumours relative to Arpin mRNA.
|
Prognosis status |
Arpin status |
|||||
|---|---|---|---|---|---|---|
| Total population (%) | Metastases (%) | P-valuea | Arpin mRNA under expressed | Arpin mRNA normally expressed | P-valueb | |
| Total | 454 (100.0) | 167 (36.8) | 33 (7.3) | 421 (92.7) | ||
|
Age (years) | ||||||
| ⩽50 | 97 (21.4) | 36 (21.6) | 0.63 (NS) | 9 (27.3) | 88 (20.9) | 0.39 (NS) |
| >50 | 357 (78.6) | 131 (78.4) | 24 (72.7) | 333 (79.1) | ||
|
SBR histologic gradec,d | ||||||
| I | 58 (13.0) | 8 (4.9) | 0.00011 | 1 (3.0) | 57 (13.8) | 0.014 |
| II | 228 (51.2) | 83 (50.9) | 13 (39.4) | 215 (52.2) | ||
| III | 159 (35.7) | 72 (44.2) | 19 (57.6) | 140 (34.0) | ||
|
Lymph node statuse | ||||||
| 0 | 119 (26.3) | 35 (21.0) | 0.0000027 | 10 (30.3) | 109 (26.0) | 0.85 (NS) |
| 1–3 | 237 (52.3) | 77 (46.1) | 16 (48.5) | 221 (52.6) | ||
| >3 | 97 (21.4) | 55 (32.9) | 7 (21.2) | 90 (21.4) | ||
|
Macroscopic tumour sizef | ||||||
| ⩽25 mm | 222 (49.8) | 62 (37.3) | 0.000017 | 11 (33.3) | 211 (51.1) | 0.050 |
| >25 mm | 224 (50.2) | 104 (62.7) | 22 (66.7) | 202 (48.9) | ||
|
ERα status | ||||||
| Negative | 116 (25.6) | 48 (28.7) | 0.021 | 11 (33.3) | 105 (24.9) | 0.29 (NS) |
| Positive | 338 (74.4) | 119 (71.3) | 22 (66.7) | 316 (75.1) | ||
|
PR status | ||||||
| Negative | 192 (42.3) | 83 (49.7) | 0.0024 | 19 (57.6) | 173 (41.1) | 0.065 (NS) |
| Positive | 262 (57.7) | 84 (50.3) | 14 (42.4) | 248 (58.9) | ||
|
ERBB2 status | ||||||
| Negative | 357 (78.6) | 127 (76.0) | 0.17 (NS) | 28 (84.8) | 329 (78.1) | 0.37 (NS) |
| Positive | 97 (21.4) | 40 (24.0) | 5 (15.2) | 92 (21.9) | ||
|
Molecular subtypes | ||||||
| HR− ERBB2- | 68 (15.0) | 26 (15.6) | 0.032 | 8 (24.2) | 60 (14.3) | 0.38 (NS) |
| HR− ERBB2+ | 43 (9.5) | 21 (12.6) | 3 (9.1) | 40 (9.5) | ||
| HR+ ERBB2- | 289 (63.7) | 101 (60.5) | 20 (60.6) | 269 (63.9) | ||
| HR+ ERBB2+ | 54 (11.9) | 19 (11.4) | 2 (6.1) | 52 (12.4) | ||
a
Abbreviations: NS=not significant; SBR=Scarff Bloom Richardson. Log-rank test. P⩽0.05 are shown in bold.
b
χ2 test.
c
SBR classification.
d
Information available for 445 patients.
e
Information available for 453 patients.
f
Information available for 446 patients.